Boehringer Ingelheim to present early clinical evidence of innate immune modulation and anti-tumor activity via SIRPα blockade in two ongoing trials at ASCO 2025
· BI 765063 in combination with programmed cell death-1 (PD1) inhibitor antibody ezabenlimab + cetuximab demonstrated a well-tolerated safety profile and potentially promising efficacy signals as second-line treatment in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
·
Next generation SIRP
α
inhibitor BI 770371 was shown to be well tolerated alone and in combination with PD1 inhibitor ezabenlimab in a dose escalation trial in patients with advanced solid tumors. BI 770371 is currently being further investigated in a Phase 1b study in first-line patients with R/M HNSCC.
Ingelheim, Germany, 22 May 2025 – Boehringer Ingelheim today announced that new clinical data from two early-stage trials targeting the signal regulatory protein α (SIRPα) innate immune checkpoint will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, May 30 – June 3, 2025, in Chicago, IL, USA.
Advertisement
In a Phase 1b study conducted by Boehringer, its potential, first-in-class SIRPα monoclonal antibody, BI 765063, demonstrated a manageable safety profile as well as preliminary signs of immune activation and additive antitumor activity when combined with PD-1 inhibitor ezabenlimab and cetuximab in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).[1]
Additionally, in an open-label, Phase I trial conducted by Boehringer, its next-generation SIRPα monoclonal antibody, BI 770371, alone and in combination with the PD-1 inhibitor ezabenlimab, was shown to be well tolerated in patients with advanced solid tumors. There were no dose-limiting toxicities in either treatment arm, and the maximum tolerated dose was not reached in either group.[2]
'The preliminary results from these early-stage programs are encouraging and further strengthen Boehringer's robust immuno-oncology pipeline aimed at accelerating next-generation cancer therapies to address high unmet patient needs,' said Mike Akimov, Head of Medicine, Therapy Area Oncology at Boehringer Ingelheim. 'Boehringer is developing various complementary approaches to activate the immune system against cancer cells and SIRPα blockade paired with a PD-1 inhibitor is a promising strategy. We look forward to seeing if this dual activation may lead to a broader and more sustained anti-tumor response as the programs progress.'
BI 765063 and BI 770371 are designed to block the 'don't eat me' signal that cancer cells use to hide from the immune system. By targeting SIRPα, these antibodies help immune cells like macrophages recognize and destroy tumor cells, bolstering the body's natural defenses.[3]
Both antibodies have been developed in partnership with OSE, with Boehringer solely responsible for future clinical development and commercialization. Boehringer will move forward with the improved next generation SIRPα inhibitor antibody BI 770371, which will now be tested in a Phase 1b study.
Presentation Details:
Title: An Open-Label, Phase Ib Trial of the SIRPα Inhibitor BI 765063 in Combination with the PD-1 Inhibitor Ezabenlimab and Cetuximab in Patients (pts) with Head and Neck Squamous Cell Carcinoma
Abstract Number: 6019
Session Type/Title: Rapid Oral Abstract – Developmental Therapeutics – Immunotherapy
Date/Time: 01 June 2025 – 11:30am – 1:30pm CDT
Title: An Open-label, Phase I Trial of the SIRPα Monoclonal Antibody, BI 770371, Alone and in Combination with the PD-1 Inhibitor Ezabenlimab in Patients with Advanced Solid Tumors
Abstract Number: 2515
Session Type/Title: Rapid Oral Abstract – Developmental Therapeutics – Immunotherapy
Date/Time: 01 June 2025 – 11:15am – 12:45pm CDT
Boehringer Ingelheim
Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer Ingelheim takes a long-term perspective, embedding sustainability along the entire value chain. More than 54,500 employees serve over 130 markets to build a healthier, more sustainable and equitable tomorrow. Learn more at https://www.boehringer-ingelheim.com (Global).
OSE Immunotherapeutics
OSE Immunotherapeutics is a biotech company dedicated to developing first-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&I) that address the unmet patient needs of today and tomorrow. We partner with leading academic institutions and biopharmaceutical companies in our efforts to develop and bring to the market transformative medicines for people with serious diseases. OSE Immunotherapeutics is based between Nantes and Paris and is quoted on Euronext.
Additional information about OSE Immunotherapeutics assets is available on the Company's website: www.ose-immuno.com. Click and follow us on LinkedIn.
Intended Audiences Notice
This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.
Forward-looking statements
This press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics' management considering its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate.
These forward-looking statements include statements typically using conditional and containing verbs such as 'expect', 'anticipate', 'believe', 'target', 'plan', or 'estimate', their declensions and conjugations and words of similar import. Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics' shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance. This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF on April 30, 2024, including the annual financial report for the fiscal year 2023, available on the OSE Immunotherapeutics' website. Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements.
Contacts
Boehringer Ingelheim
OSE Immunotherapeutics
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
9 hours ago
- Business Insider
Why Wall Street's Dr. Doom now wants to be Dr. Boom
Wall Street has been calling him "Dr. Doom" for 17 years, but Nouriel Roubini — the economist famous for his persistently bearish and frequently dystopian takes on the world economy — is sounding surprisingly positive lately. He's rescinded his earlier call for a recession, and now sees a US tech and artificial intelligence investment boom unfolding that will uplift the economy through the rest of this decade. By 2030, Roubini thinks economic growth in the US will double from around 2% to 4%, while productivity growth surges from around 1.9% to 3%. The stock market is also likely to climb higher, he told Business Insider in an interview, predicting the S&P 500 would see high single-digit percentage growth in 2025, on par with its historical return. It's a sharp turnaround from the gloomy forecasts he' is known for. Roubini told BI the nickname started to stick in 2008, when the New York Times referred to him as " Dr. Doom" after he correctly called the Great Financial Crisis, he told BI. "Even before, I always said I'm not Dr. Doom and I'm Dr. Realist, first of all," Roubini said. He said that he's made numerous forecasts that were more bullish than the consensus throughout the years when the evidence lines up. "So I don't know why people think that I'm always Dr. Doom. It's not the case." His outlook, though, has brightened considerably since 2022. Back then, he appeared on TV and penned op-eds warning of a coming stagflationary debt crisis. At the time, he described the turmoil he saw looming as an all-in-one financial crisis involving spiraling debt levels, soaring inflation, and a severe recession. Roubini told BI there are a few things that have gotten him to change his tune. 1. Artificial Intelligence Roubini says he began to hear the murmurs of the AI revolution well before ChatGPT went viral at the end of 2022. In his 2022 book, "Megathreats," he acknowledged the potential for artificial intelligence to significantly boost economic growth and serve as a major tailwind for markets. That's become a reality way faster than Roubini expected, and a major reason he's become more bullish, he told BI. He believes the economy could start to reap the growth and productivity benefits of AI in the next several years, particularly as humanoid robots enter the mainstream. 2. An energy revolution A breakthrough in fusion energy would be another bullish force for the economy, Roubini said. Fusion energy hasn't been achieved yet, but tech firms are pouring vast sums of money into making it happen. Chevron and Google contributed to a more than $150 million funding round this week for TAE Technologies, a fusion energy company that plans to have a working prototype power plant by the early 2030s. Type One Energy, another fusion energy firm, also plans to roll out a power plant by the middle of the next decade. "We're not in an AI winter anymore. We had the fusion winter for 40 years. We're not anymore," Roubini said, pointing to the stagnation in tech and fusion energy development is the past. "Now it's happening." 3. Markets are checking Trump President Donald Trump's tariffs may not be as harmful to the US economy as some investors think, Roubini says. He thinks it's more likely that markets will throw a tantrum and force Trump to walk back his most aggressive policies. That's already happened a few times this year. Roubini pointed to sharp sell-offs in the bond market that preceded Trump's 90-day pause of his "Liberation Day" tariffs, and the softening of his tone regarding firing Jerome Powell. "That means the bond vigilantes are the most powerful people in the world," Roubini said. "The instincts might be very bad, but then, markets are unforgiving," he added of policymakers. Roubini speculates that tariffs on China, for instance, could wind up somewhere around 39%, well-below the 145% tariff rate Trump proposed earlier in the year. Meanwhile, AI, quantum computing, and other tech advancements in the US can more than offset the impact of the trade war, Roubini said. Tariffs are expected to drag down GDP growth by 0.06% a year through 2035, according to estimates from the Congressional Budget Office. It's a fraction of the 2 percentage point increase in growth Roubini expects to see by the end of the decade. Roubini now pegs the odds of a recession to just around 25%. Even if the US enters a downturn this year, Roubini says he expects it to be shallow and short, as the Fed can cut interest rates to boost the economy, while tech powers growth over the long-run. That's not to say Dr. Doom has shed all of his bearish views. Roubini says many of the things he feared several years ago — stagflation, spiraling government debt levels, and rising geopolitical conflict — still loom. He rattled off a list of potential risks the US could conceivably face in the future: migration controls fueling stagflation in the economy, the US dollar collapsing in value, and China and the US not reaching a trade agreement and seeing an escalating cold war, to name a few scenarios. "So there's plenty of stuff in the world that can go wrong," he said.
Business Insider
9 hours ago
- Business Insider
The dos and don'ts of networking
You might be networking all wrong — and that could be more detrimental than ever before. In the age of AI-generated applications and a tough market for many desk workers, making connections can be key to landing a job. Career coaches and etiquette experts told Business Insider about some of their dos and don'ts of networking. Be specific Too often, people blast out generic LinkedIn messages that will never stand out. "You can't go into it cold," Jasmine Escalera, a career expert with MyPerfectResume, told BI, referring to networking. "That doesn't mean that you can't go into it making a cold connection, but you can't go into it just without a connection." That connection doesn't always have to be strictly professional, Escalara said. You could, for example, find a common hobby. When it comes to online outreach, send a tailored message instead of a boilerplate one. Madeline Mann, a career coach and CEO of Self Made Millennial, offered similar advice. "If you're going to ask for 15 minutes of their time, be sure to show that you spent 15 minutes of yours," she said. Generally, though, social media alone isn't enough. Brandon Dock, managing director of the recruitment firm TGC Search, said that talking to people in person is always best. "I have always been a fan of using social media and other online tools as part of your arsenal, but it is a grave mistake to think of it as the entirety of your networking strategy," Dorie Clark, a communication coach who teaches at Columbia Business School and wrote the book "The Long Game," told BI. Keep it professional — even online While it's great to bond over hobbies, it's crucial to maintain professionalism. At in-person events, that often means limiting alcohol to one glass, Escalera said. On social media platforms you're using for outreach, she said to maintain a "professional tone" and "tight brand." Gen Zers can sometimes struggle to balance between professionalism and friendliness, Escalera and Lisa Richey, the founder of the American Academy of Etiquette, said. "The formality of a handshake — you can never go wrong," Richey said. "It shows leadership. It shows confidence." Dress for the industry Now that in-person schmoozing is back, dressing the part is crucial, but each industry requires a slightly different look. "Dress the way someone would in that office or in the industry, with a step up," Mann said. She said that no matter your gender, a button-down top is a safe bet. Escalera advised sticking to one statement piece. It's important to tailor your clothing to the industry. Mann said, for example, that a suit might look odd at a tech event, but it's perfectly normal among lawyers. The same rules apply online, Richey said. "You have to be aware of what's going on behind you, your hair," she told BI. "You have to be groomed. You have to dress the part, even if it's an online meeting." Don't wait until you need a job People often only start networking when they need a job, but experts told BI that can be a mistake. "Whenever there's an economic down cycle and people start to get worried about their jobs, that is inevitably when networking accelerates," Clark said. To avoid becoming just one among many asking for a favor, you should maintain relationships even when you're secure in a job. Texting with closer connections is an underrated tool, according to Clark, who advised reaching out when you're not looking for anything in return. Keeping up relationships doesn't follow a cookie-cutter template. Mann said that connections can come from the unlikeliest of places, so it's important to chat about your interests frequently. "Never underestimate who knows the person you want to know," she said — maybe your barber's cousin works at your dream company. Don't make it all about you Experts said that too many people only highlight their experiences. "Don't focus on knowing people. Focus on noticing people," Mann said. Both she and Escalera suggest coming up with specific questions for people you find exciting. "Having a good elevator pitch is really awesome, but what we don't want to do is make it all about you," Escalera said, which can make the process feel "robotic." Don't ask for too much Networking is necessarily transactional, but that transaction can be a delicate dance, the experts said. "You have to be cognizant of power relations and power differentials in networking," Clark said, noting you can ask a friend for more favors than a distant connection. "You need to be very targeted and strategic about your ask, and you can probably only get away with asking them one thing," she added. Mann thinks about it as flipping the switch from asking to giving — instead of just trying to extract information, consider what you can offer the other person, even if it's something as simple as tips for a coming vacation. No matter the conversation, gratitude is key. "Do not forget to follow up with them the next day or within a few hours, thanking them," Mann said. "And do not forget within the coming weeks to say how you utilize their insights."
Business Insider
10 hours ago
- Business Insider
Our favorite photos from Bitcoin 2025
From May 27 to 29, some 35,000 people gathered at the Venetian Expo Center in Las Vegas for Bitcoin 2025, the world's largest annual gathering of bitcoin industry professionals and enthusiasts. As Jacob Silverman reports in a feature dispatch from the conference for Business Insider, "More than anything, Bitcoin 2025 was a victory celebration for an industry that pushed all its chips in behind Donald Trump and the Republican Party during the 2024 election cycle and won handsomely." This year's speakers included Vice President JD Vance, Eric Trump and Donald Trump Jr., White House crypto and AI czar David Sacks, Sen. Jim Justice (who shared the stage with his bulldog, Babydog), Ohio gubernatorial candidate Vivek Ramaswamy, and the recently pardoned Silk Road drug market founder Ross Ulbricht. BI also sent photographer David Becker to cover the conference, and his photos captured the energy and triumphalism of the sprawling bitcoin community today.
